Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR

Subclass of:

424 - Drug, bio-affecting and body treating compositions

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424282100 Bacterium or component thereof or substance produced by said bacterium 28
424283100 Lipid or oil 14
424281100 Virus (e.g., interferon-inducing virus, etc.) 9
424279100 Synthetic or structurally-modified peptidoglycan or mucopolysaccharide or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D-glutamic or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D- acid, etc.) glutamic acid, etc.) 1
20090214598Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease - The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each covalently attached. The first epitope comprises one or more than one generic T helper peptide sequence, and the second epitope comprises one or more than one target epitope. The first and second epitopes are present in one or more copies each within the SPA. Each target epitope is a peptide sequence or a carbohydrate moiety, and is an immunogen to CD8+ T cells or B cells. The present invention also provides a suppressive synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which one or more than one target epitope is covalently attached. Each target epitope is a peptide sequence or carbohydrate moiety and is present in one or more copies within the SPA.08-27-2009
424280100 Synthetic polymer or copolymer 1
20080292663ADJUVANT COMPOSITIONS AND METHODS FOR DELIVERING VACCINES - An adjuvant composition is provided that is comprised of a calcium compound, lecithin, and an acrylic polymer. Pharmaceutical compositions are provided which include an antigen and the adjuvant. Methods are provided for stimulating an immune response in a human or animal subject by administering a composition comprising an antigen and the adjuvant composition to human or animal subjects.11-27-2008
Entries
DocumentTitleDate
20100119556METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOGENIC OLIGONUCLEOTIDES - This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.05-13-2010
20130183348Inhibitor of HMGB Protein-Mediated Immune Response Activation, and Screening Method - Provided are an inhibitor of activation of an immune response mediated by an HMGB protein, the inhibitor containing at least one compound selected from the group consisting of a phosphorothioate oligonucleotide and a derivative thereof, and a method of screening for an inhibitor or enhancer of activation of an immune response mediated by an HMGB protein, the method including a mixing step of mixing an HMGB protein and a labeled nucleic acid in the presence and absence of a test substance; a quantifying step of quantifying the HMGB protein bound to the labeled nucleic acid; and a determination step of determining that the test substance is an inhibitor of activation of an immune response mediated by the HMGB protein when the amount of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is less than the amount of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance and determining that the test substance is an enhancer of activation of an immune response mediated by the HMGB protein when the amount of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is higher than the amount of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance.07-18-2013
20130183347Somatic Transgene Immunization and Related Methods - The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell.07-18-2013
20110195094TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.08-11-2011
20120183579COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.07-19-2012
20120183578POLYETHYLENE GLYCOL-BASED DENDRONS - The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use.07-19-2012
20120183577COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides processes for preparing the compounds, pharmaceutically acceptable compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders.07-19-2012
20130078280CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA03-28-2013
20130039948Inhibition of TCR Signaling with Peptide Variants - The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).02-14-2013
20130136771OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE - A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula:05-30-2013
20130045236DIAGNOSTIC AND THERAPEUTIC USES OF SOLUBLE FC-EPSILON RECEPTOR I FOR IGE-MEDIATED DISORDERS - The present disclosure is based in part on the finding that sFcεRI is a novel biomarker for IgE-mediated disorders. Methods for diagnosing, treating and/or monitoring IgE-mediated disorders are also described. The disclosure further provides assays to detect sFcεRI in a sample.02-21-2013
20090041809DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS - Immunostimulatory agents, including nucleic acids having one or more than one locked nucleic acid (LNA) nucleosides are provided. The nucleic acids may further comprise CpG motifs. The nucleic acids may be double stranded, and may comprise dsRNA.02-12-2009
20130071437IMMUNOLOGICAL FUNCTION ENHANCING AGENT - An agent, as an active ingredient thereof, includes activated lymphocytes derived from a tissue of an animal, in which antibodies and immunocytes do not pass from a mother to a fetus across the placenta, and which is used to enhance the immunological functions of another animal of the same species as the animal from which the lymphocytes are derived. A method for producing an agent for enhancing immunological functions of another animal, in which lymphocytes isolated from an animal are grown and activated to produce activated lymphocytes.03-21-2013
20130071435NOVEL HERBAL FORMULATION FOR THE MODULATION OF IMMUNE SYSTEM OF HIV INFECTED PATIENTS AND A PROCESS OF PREPARATION THEREOF - An herbal formulation for the modulation of immune system of HIV infected patients and a process of preparation thereof are provided. The process includes (i) preparing a hydromethanolic extract of at least one plant selected from Hippophae rhamnoides, 03-21-2013
20130071436TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.03-21-2013
20090092641USES OF NATURAL IMMUNOBIOTIC EXTRACT - The present invention provides a method of improving disease management in an animal by administering an effective amount of β-glucan composition to the animal. The β-glucan composition comprises at least about 70% β-(1,3/1,6)-D-glucan by dry weight and a biological activity of at least 20 μg Bb released per mg of β-(1,3/1,6)-D-glucan. The method may also result in beneficial secondary effects including an increase in growth efficiency of the animal; an increase in the survival rate of the animal; an increase in the colostrum quality of the animal; and any combination thereof. The β-glucan composition may also be administered in combination with or prior to a vaccine, leading to an increase in antibody formation; the negative growth responses associated with administration of a vaccine may also be reduced. In the present method, the β-glucan composition may be administered in combination with an animal feed.04-09-2009
20130058980SMALL MOLECULE INHIBITORS OF PROTEIN KINASES - Compounds that modulate, for example, that inhibit, syk kinase, and, optionally other kinases. The compounds can be used to treat a variety of disorders, including inflammatory disorders and autoimmune disorders.03-07-2013
20120225096IMMUNOMODULATION USING PLACENTAL STEM CELLS - The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.09-06-2012
20120225095PRODUCTION OF CARBOXYLIC ACID AND SALT CO-PRODUCTS - This invention provide processes for producing carboxylic acid product, along with useful salts. The carboxylic acid product that is produced according to this invention is preferably a C09-06-2012
20130064858POLYSACCHARIDE SUITABLE TO MODULATE IMMUNE RESPONSE - Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species 03-14-2013
20120195930NOVEL PYRIDINE DERIVATIVES - The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.08-02-2012
20120114700LAT ADAPTER MOLECULE FOR ENHANCED T-CELL SIGNALING AND METHOD OF USE - LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods.05-10-2012
20120237553Process to Obtain a Homeopathic Medicament and Use Thereof - The present invention concerns a process to obtain a biological response modifier (BRM), particularly a medicament, as well as the medicament thus obtained and its use from highly diluted associations of vegetable, mineral and animal extracts, aiming to make use of its medicinal characteristics, internally and externally, in treatment, prevention, control and elimination of diseases, therapeutic and aesthetic finalities, in human beings.09-20-2012
20120237552Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments - Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines. In addition these molecules were able to ameliorate acute experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) animal model, inhibiting brain inflammation and reducing brain damage. We also observed suppression in the production of pro-inflammatory genes like the inducible nitric oxide synthase. These small molecules with NGF agonist activity may be beneficial for MS and other neurodegenerative diseases due to its neuroprotective and immunomodulatory properties.09-20-2012
20120237551IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.09-20-2012
20130164333IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES - Immunostimulatory oligoribonucleotides (ORN) featuring 5′-triphosphates and various 5′-triphosphate analogs are provided. Also provided are physiologically acceptable salts of the immunostimulatory ORN and pharmaceutical compositions containing the immunostimulatory ORN of the invention. ORN of the invention are useful as adjuvants and can be combined with an antigen to promote an antigen-specific immune response. ORN of the invention are also particularly useful for promoting a Th1-type immune response. Also provided are methods of use of the compounds and pharmaceutical compositions of the invention to enhance an immune response in a subject, as well to treat a number of conditions including cancer, infection, allergy, and asthma, and to vaccinate a subject against an antigen.06-27-2013
20130017226TNF-A and TWEAK Dual Antagonist for the Prophylaxis and Treatment of Autoimmune DiseasesAANM Park; Young WooAACI DaejeonAACO KRAAGP Park; Young Woo Daejeon KRAANM Jo; Ki WonAACI Gyeonggi-doAACO KRAAGP Jo; Ki Won Gyeonggi-do KRAANM Yoo; Srok HoAACI DaejeonAACO KRAAGP Yoo; Srok Ho Daejeon KRAANM Yu; JungAACI DaejeonAACO KRAAGP Yu; Jung Daejeon KRAANM Kim; Dong JiAACI DaejeonAACO KRAAGP Kim; Dong Ji Daejeon KRAANM Yoon; Sun-HaAACI DaejeonAACO KRAAGP Yoon; Sun-Ha Daejeon KRAANM Song; Eun JungAACI DaejeonAACO KRAAGP Song; Eun Jung Daejeon KRAANM Lee; Eun KyungAACI Gyeonggi-doAACO KRAAGP Lee; Eun Kyung Gyeonggi-do KRAANM Oh; Jin MiAACI Gyeonggi-doAACO KRAAGP Oh; Jin Mi Gyeonggi-do KRAANM Cho; Kyu WonAACI SeoulAACO KRAAGP Cho; Kyu Won Seoul KRAANM Cho; Mi LaAACI SeoulAACO KRAAGP Cho; Mi La Seoul KRAANM Kim; Ho YounAACI SeoulAACO KRAAGP Kim; Ho Youn Seoul KRAANM Park; Mi KyungAACI Gyeonggi-doAACO KRAAGP Park; Mi Kyung Gyeonggi-do KRAANM Oh; Hye JwaAACI SeoulAACO KRAAGP Oh; Hye Jwa Seoul KRAANM Park; Jin SilAACI SeoulAACO KRAAGP Park; Jin Sil Seoul KRAANM Woo; Yun JuAACI SeoulAACO KRAAGP Woo; Yun Ju Seoul KRAANM Byun; Jae KyeongAACI Chungcheongbuk-doAACO KRAAGP Byun; Jae Kyeong Chungcheongbuk-do KRAANM Ryu; Jun GeolAACI Gangwon-doAACO KRAAGP Ryu; Jun Geol Gangwon-do KR - The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-α and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.01-17-2013
20110052643COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.03-03-2011
201200032706-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND USES THEREOF - The present invention relates to 6-substituted isoflavonoid compounds and compositions comprising same. The invention further relates to the use of 6-substituted isoflavonoid compounds for the treatment of various diseases and conditions.01-05-2012
20110287059HONEY ANALYSIS - A number of methods of analysing honey are described to determine the age of the honey, the presence of fortification with additives including methylglyoxal (MGO), the region from which the honey is derived, the plant species from which the honey is derived and whether the honey has been heated during processing. The various characteristics are determined based on the phenolic concentrations in the honey which have been found to provide very clear markers for the above characteristics. The methods of analysis described have many applications, particularly around quality assurance and ensuring that honeys are true to labeled specifications.11-24-2011
20100166805Modulation of immunostimulatory properties by small oligonucleotide-based compounds - The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.07-01-2010
20090148479METHODS OF MODULATING AN IMMUNE RESPONSE USING IMMUNOSTIMULATORY SEQUENCES AND COMPOSITIONS FOR USE THEREIN - The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.06-11-2009
20110014242PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARA - The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.01-20-2011
20100112012MODULATION OF IMMUNE RESPONSES - Compositions and methods for modulating an NF-05-06-2010
20080286316Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods - The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.11-20-2008
20120141538MODULATORS OF THE CX3CRI RECEPTOR AND THERAPEUTIC USES THEREOF - The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.06-07-2012
20120034270S1P Receptors Modulators - The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.02-09-2012
20120294895PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg.11-22-2012
20120294896Methods and Compositions for Poxvirus A35R Protein - The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.11-22-2012
20100098730IMMUNOGLOBULIN VARIANTS AND USES THEREOF - Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided.04-22-2010
20130216587POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment08-22-2013
20080241196Artificial invaplex - An artificial invasin complex is prepared from purified or recombinantly prepared invasins and gram negative bacteria lipopolysaccharides. Typically, IpaB is mixed with IpaC to form a IpaB:IpaC complex. This invasin protein complex is then mixed with the lipopolysaccharide to form an artificial invasin complex. Additional bioactive molecules can be incorporated into the complex during manufacture. This artificial invasin complex is similar in function to native Invaplex 24 or Invaplex 50. The artificial invasin complex has superior immunogenicity properties relative to the native complex and can be taylor made. Its method of preparation lends itself to scale up. The artificial invasin complex can facilitate transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex.10-02-2008
20100203087CHEMOREPULSION OF CELLS - The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.08-12-2010
20120070463METHOD OF BIOTECHNOLOGICAL PRODUCTION FO BOVINE HEMODERIVATIVE AND USE OF BOVINE HEMODERIVATIVE - The method of biotechnological production of bovine hemoderivative is presented in the following overview providing a summary of individual technological operations in time sequence (Flow-Sheet).03-22-2012
20130216585COMPOSITION AND METHODS FOR QUENCHING FREE RADICALS AND MODULATING INFLAMMATION - Compositions and methods useful in quenching free radicals, the compositions including dihydroquercetin, vitamin C and Arabinogalactan, specifically, larch arabinogalactan, effective to enhance the immune modulating properties of Larch Arabinogalactan by quenching the free radicals that initiate a cascade of oxidative stress and inflammation.08-22-2013
20110229525MODULATION OF CYTOKINE SIGNALING - Cell penetrating suppressor of cytokine signaling (CP-SOCS) molecules engineered to be resistant to intracellular degradation are discussed. Methods of treating diseases associated with cytokine signaling include one or more CP-SOCS degradation resistant molecules.09-22-2011
20090004227Peroral Vaccine Carrier System - The present invention provides a system in which a recombinant plant expressing a target peptide is orally administered to thereby achieve exertion of the function of the peptide, along with the genetically recombinant plant, and the present invention relates to a carrier system for oral administration of a target peptide by oral administration of a plant (potato) that expresses a target peptide by expressing for example a fused gene obtained by fusing the LRE1 gene coding for the immunogenic peptide LRE1 derived from the 01-01-2009
20120195929COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME - The invention provides methods of preventing, treating or ameliorating autoimmune diseases such as diabetes by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.08-02-2012
20100255040COMPOSITION FOR IMPROVING TLR-MEDIATED CELLULAR IMMUNITY COMPRISING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to a composition for improving cellular immunity, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a composition for improving cellular immunity comprising poly-gamma-glutamic acid, which has effects of inducing enhancement of TLR-mediated Th1 cellular immunity and improving antigen presenting activity to maintain the improved activity. The inventive composition comprising an effective dose of poly-gamma-glutamic acid has very little toxicity and side effects, and can be added to a vaccine composition for preventing and treating animal viral or bacterial infections and cancer, or a vaccine composition for preventing and treating human viral or bacterial infections and cancer to show cellular immunity-enhancing effects.10-07-2010
20090017077Compounds and methods for immunotherapy and diagnosis of tuberculosis - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more 01-15-2009
20130216586ANIMAL FEED COMPOSITIONS AND METHODS OF USING THE SAME - Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from 08-22-2013
20120141539METHODS FOR MODULATING TOLL-LIKE RECEPTOR MEDIATED ACTIVATION OF CELLS OF THE INNATE SYSTEM BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the activity of XBP-I protein, or a protein in a signal transduction pathway involving XBP-I to modulate the TLR-mediated activation of cells of the innate immune system. Enhancing the TLR-mediated activation of cells of the innate immune system enhance inflammatory responses. The present invention also pertains to methods for identifying compounds that modulate Toll-like receptor-mediated signaling.06-07-2012
20120141541SYNERGISTIC MIXTURE OF BETA-GALACTO-OLIGOSACCHARIDES WITH BETA-1,3 AND BETA-1,4/1,6 LINKAGES - The present invention relates to a nutritional composition comprising at least two different beta-galacto-oligosaccharides (BGOS) A and B wherein the majority of linkages between two galactose residues in BGOS A are beta 1,4 and/or beta 1,6, and the majority of linkages between two galactose residues in BGOS B are beta 1,3. Such mixtures show superior effects on the immune system and are particularly suitable for infant nutrition.06-07-2012
20120141540Drug Delivery System - Red blood cells can be used as effective drug delivery systems when they contain proteins that do not readily diffuse out and which form affinity complexes with the desired drug.06-07-2012
20130136770METHODS FOR TREATING RESPIRATORY VIRAL INFECTION - Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.05-30-2013
20130136772REGULATION OF IMMUNE RESPONSE BY COLOCYNTHIN AND/OR ITS DERIVATIVES - The present invention relates to a method of inhibiting pro-inflammatory and T-cell mediated cytokines, said method comprising step of administering to a subject in need thereof a therapeutically effective amount of colocynthin and/or its derivatives. The invention also relates to a method of inhibiting T-cell surface markers and to a method of regulating immune response by colocynthin and/or its derivatives.05-30-2013
20130142832NUCLEIC ACID/ POLYSACCHARIDE COMPLEX - An object of the present invention is to provide a highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan. A nucleic acid-polysaccharide complex is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex.06-06-2013
20110008393NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 58P1D12 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.01-13-2011
20110008394ACTIVE SUBSTANCES THAT INCREASE THE ACTIVATION THRESHOLD OF IMMUNE CELLS - The present invention relates to the use of active substances that increase the activation threshold of immune cell as an active principle for the preparation of a cosmetic or pharmaceutical composition, especially a dermatological composition. The invention also relates to a method for screening such active substances.01-13-2011
20110045027Adjuvant - The present invention provides a novel adjuvant for polynucleotide vaccines, and in particular the present invention provides immunogenic compositions comprising a polynucleotide encoding an antigen capable of eliciting an immune response and an adjuvant comprising an immunostimulatory quantity of a gemini surfactant, or a derivative thereof.02-24-2011
20110250235PRODUCTION OF A SACCHARIDE COMPOSITION COMPRISING GLUCANS AND MANNANS BY ALKALINE AND ACID HYDROLYSIS OF YEAST CELLS - The present invention is directed to a method of production of an immunostimulatory composition having a saccharide fraction, the method including the steps of hydrolyses of yeast cells and recovering the soluble fraction. The saccharide fraction having composition thus obtained may be incorporated as a food or beverage component or be used as a pharmaceutical for treatment of specific conditions.10-13-2011
20100239615COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.09-23-2010
20110070270IMMUNOSTIMULATING AGENT - An immunostimulating agent, which can stimulate immunity effectively, is described. The immunostimulating agent contains an active ingredient including a calcium receptor activator such as γ-Glu-X-Gly [wherein X represents an amino acid or a derivative thereof other than Cys], γ-Glu-Val-Y [wherein Y represents an amino acid or a derivative thereof], γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, γ-Glu-Cys(S-Me), a cation having a valency of 2 or more, protamine, polylysine, spermine, spermidine, putrescine, cinacalcet, a cinacalcet analogue compound, and a salt of any one of the aforementioned components.03-24-2011
20100003288CpG DNA Adjuvant in Avian Vaccines - A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a plurality of TCG tandem repeats at a 5′end, a poly-G structure at a 3′ end, and at least one unmethylated CpG motif with avian specific flanking sequences at two ends thereof between the 5′ end and the 3′ end. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.01-07-2010
20080268000Vaccine Stabilising Formula with Live Antigens for Use in Mass Vaccination Systems - The invention relates to a vaccine stabilizing formula with live antigens for use in mass medication and vaccination systems which are used in animal protein production processes. The invention comprises a product in the form of a powder or liquid to enable the same to be solubilized in water formed by a homogeneous mixture of compounds of organic and inorganic origin. The invention can be used to stabilize the critical physicochemical parameters of the water upon vaccination (pH, hardness and presence of disinfectants), thereby reducing the microbial and viral liter loss of the vaccine caused by environmental exposure upon vaccination. The inventive formula is intended to be used in drinking water medication and vaccination systems and in spray medication and vaccination systems.10-30-2008
20080254072Method For Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens - Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided.10-16-2008
20100285072Method for Producing Dendritic Cells - The present invention relates to a method for producing dendritic cells and their use in medicaments by genetic engineering aimed at functionally improving their therapeutic efficacy in the treatment of cancer, microbial infections, allergies, auto-immune diseases or organ and stem cell transplant rejection.11-11-2010
20110262485STING (STIMULATOR OF INTERFERON GENES), A REGULATOR OF INNATE IMMUNE RESPONSES - Novel molecules termed STING which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. STING compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity10-27-2011
20110052644COMPOSITION COMPRISING EXTRACT OF CINNAMOMUM CASSIA BARK FOR IMPROVING NORMAL FLORA AND ENHANCING IMMUNE RESPONSE - The present invention relates to a composition for improving intestinal flora and enhancing immune response containing 03-03-2011
20120207789TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg.08-16-2012
20120308608INTERFERON-INDUCING COMPOUNDS AND USES THEREOF - Provided herein are Compounds that induce interferon production and methods for identifying such Compounds. Also provided herein are compositions comprising such Compounds and methods of using such Compounds to treat interferon-sensitive diseases such as viral infections, cancer, and multiple sclerosis.12-06-2012
201203086096-AMINO-2--9-[5-(1-PIPERIDINYL)-7,9-DIHYDRO-8H-PURIN-8-ONE MALEATE - The present invention relates to a compound which is 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one:12-06-2012
20120308607PRODUCTION AND USE OF HUMAN CD124- AND CD-116-POSITIVE TUMOR CELL LINES IN THE PRODUCTION OF ALLOGENIC OR SEMI-ALLOGENIC IMMUNOTHERAPY AGENTS - The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and yeast systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.12-06-2012
20120308606BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS - Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.12-06-2012
20100322976TONIC AND FOOD SUPPLEMENT COMPRISING ALOE VERA AND HONEY - A mixture of honey (preferably manuka honey) with aloe vera extract is concentrated for distribution and then diluted before use as a tonic or food supplement for mammals, particular those with compromised or poorly performing immune systems. In particular (though without limit) the composition is useful in the control of chronic mastitis in dairy cows.12-23-2010
20110117136DEHYDROEPIANDROSTERONE PRODUCTION PROMOTER AND USE THEREOF - A new orally administerable DHEA production promoter is provided. A composition containing an extract of at least one selected from the group consisting of plants of Rosaceae 05-19-2011
20110305730MONO-AND DISACCHARIDE DERIVATIVES - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications.12-15-2011
20110305729Scriptaid Isosteres and Their Use in Therapy - Compounds of the invention are of the formula (I); wherein: 12-15-2011
20120039945Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system.02-16-2012
20120039944WHEY AND THYMUS FUNCTION - The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that can be used to maintain or improve thymus health. One embodiment of the present invention is the use of whey or at least one protein fraction thereof for the preparation of a composition to maintain or improve thymus function.02-16-2012
20130142831COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of formula (I):06-06-2013
20120301505Immunostimulating Agent and Method for Production Thereof - The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition.11-29-2012
20110064771PLANT EXTRACTS AND USES THEREOF - Plant extracts obtainable by extracting various plant materials with an alkaline agent, methods for preparing such extracts, compositions comprising such extracts, and methods for using the extracts or compositions thereof are described.03-17-2011
20120156247BIOCOMPOSITION STIMULANT OF THE IMMUNE SYSTEM, ANTI-TUMOUR AND ANTI-HIV - Provided is a herbal composition of plants obtained from non-domestic wild sources by means of meristems and the extracts thereof obtained using improved processes, in which the extracts and the active principles thereof generate a synergism demonstrating anti-inflammatory, antiviral nutritional supplement, immune system simulating, prostatic health promoting and supporting properties for improving quality of life with a wide range of benefits in individuals with chronic terminal diseases.06-21-2012
20110318388S1P Receptors Modulators and Their Use Thereof - The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.12-29-2011
20130195919INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF - The invention provides, for example, compositions comprising induced tolerogenic dendritic cells which are capable of suppressing an antigen specific T cell-mediated immune response, and to methods of making and using the same. The invention also provides compositions comprising induced immunogenic dendritic cells and methods of making and using them.08-01-2013
20120014998MODIFIED CHAPERONIN 10 - The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.01-19-2012
20120058148CERTAIN AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE - Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.03-08-2012
20120207790IMMUNOSUPPRESSING AGENT COMPRISING MESENCHYMAL STEM CELL DERIVED FROM ADIPOSE TISSUE, AND USE THEREOF - To provide an immunosuppressing agent having high therapeutic effect and uses thereof. The immunosuppressing agent includes adipose-derived mesenchymal stem cells obtained by low-serum culture.08-16-2012
20120064121PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.03-15-2012
20120064122TREATMENT OF AUTOIMMUNE INFLAMMATION USING MIR-155 - The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T03-15-2012
20120156248AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS - The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.06-21-2012
20120219594Benzimidazole-imidazole Derivatives - Inhibitors of HCV replication of formula I08-30-2012
20120121650Chimeric Virus Vaccines - The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the chimeric viral vectors and virus particles or nucleic acids (e.g., DNA and/or RNA) encoding the same to the subject.05-17-2012
20120121651PYRAZOLOPYRIDINES AND ANALOGS THEREOF - Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.05-17-2012
20100247581EDIBLE PRODUCT HAVING AN IMMUNOSTIMULATING EFFECT - There is provided an edible product having an immunostimulating effect, said product comprising immunostimulating polysaccharides obtainable from plants of the Asclepiadoideae subfamily. Also provided is a process for preparing such an edible product and a composition comprising from 0.0001 to 25% by weight of polysaccharides having an immunostimulating effect.09-30-2010
20120128725DETECTION/MEASUREMENT OF MALARIA INFECTION DISEASE UTILIZING NATURAL IMMUNITY BY HEMOZOIN INDUCTION, SCREENING OF PREVENTATIVE OR THERAPEUTIC MEDICINE FOR MALARIA INFECTION DISEASE, AND REGULATION OF NATURAL IMMUNITY INDUCTION - The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction.05-24-2012
20120315299PHARMACEUTICAL COMPOSITION FOR INTRACELLULAR ACIDIFICATION WITH CIS-UROCANIC ACID - A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.12-13-2012
20120315298LOCAL TREATMENT OF NEUROFIBROMAS - A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.12-13-2012
20120213824USE OF PUFAS FOR TREATING SKIN INFLAMMATION - The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I),08-23-2012
20100233216USE OF MICROVESICLES (MVS) FOR PREPARING A MEDICAMENT HAVING ADJUVANT ACTIVITY ON ENDOTHELIAL CELL TRANSPLANTATION, PARTICULARLY IN THE TREATMENT OF DIABETES BY PANCREATIC ISLET TRANSPLANTATION, AND RELATED METHOD - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.09-16-2010
20120135043IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.05-31-2012
20120135042Methods Using Immunomodulatory Compounds For Treatment of Certain Leukemias - Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention. The invention further relates to methods of treatment using an immunomodulatory compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.05-31-2012
20120135041IMMUNOSUPPRESSOR BASED ON THE BLOCKAGE OF TCR-NCK INTERACTION - The present invention relates to a compound of structural formula (I) and its derivatives for use as medicinal drugs. They are preferably immunosuppressive agents, with mechanism of action based on the blockage of TCR-Nck interaction.05-31-2012
20120219593INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS - A compound of formula (I)08-30-2012
20120219592Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain - A compound for therapeutic use, of the formula08-30-2012
20120171248COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more 07-05-2012
20120213823COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.08-23-2012
20120076828KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER - The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA).03-29-2012
20120177691FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT - The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.07-12-2012
20120177690USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND XENOTRANSPLANTATION - Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation.07-12-2012
20120177689GENERATION OF NOVEL BONE FORMING CELLS (MONOOSTEOPHILS) FROM LL-37 TREATED MONOCYTES - In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils.07-12-2012
20110104211COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.05-05-2011
20120258142GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.10-11-2012
20120219591USE OF VECTORS EXPRESSING INTRACELLULAR POLYNUCLEOTIDE BINDING PROTEINS AS ADJUVANTS - An object of the invention is to provide a vaccine adjuvant that is comprised of a vector capable of expressing a polynucleotide binding protein in excess of levels already present in cells. Expression of the polynucleotide binding protein initiates intracellular pathways that lead to expression of type 1 interferons. In concert with expression of type 1 interferons, other cytokines are expressed, and the immune response to vaccine antigens given with the adjuvant is enhanced.08-30-2012
20120237550Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates - Methods and reagents are disclosed for maintaining the antibody-binding activity of a conjugate of an immunosuppressant drug and a conjugative moiety. The method comprises combining with the conjugate an effective amount of a chelating agent. Compositions include in an aqueous medium (i) a conjugate of an immunosuppressant drug and a conjugative moiety and (ii) a chelating agent in an amount effective to maintain an antibody-binding activity of the conjugate of the immunosuppressant drug and the conjugative moiety. The compositions may be employed in assays for the determination of analytes that include immunosuppressant drug analytes and antibodies for an immunosuppressant drug.09-20-2012
20120225097PIPERAZINECARBOXAMIDE DERIVATIVE USEFUL AS A MODULATOR OF FATTY ACID AMIDE HYDROLASE (FAAH) - N-Pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide is described, which is useful as a FAAH inhibitor. N-Pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing N-pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide is also disclosed.09-06-2012
20120082703PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS - The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs.04-05-2012
20120082702NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS - Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds.04-05-2012
20120082701POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment04-05-2012
20120082700COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a TLR9 agonist and a TLR 2/6 agonist to the individual.04-05-2012
20120258143PHARMACEUTICAL FORMULATION AND PROCESS COMPRISING A SOLID DISPERSION OF MACROLIDE (TACROLIMUS) - The present invention relates to a pharmaceutical formulation and process for preparing the same comprising an oral dosage formulation, such as a capsule formulation, of a macrolide compound, such as tacrolimus, wherein the capsule formulation contains both a solid dispersion of the macrolide along with a non-dispersed form of the macrolide. The pharmaceutical formulation according to the invention is bioequivalent to the FDA approved product according to a bioavailability study conducted in humans.10-11-2012
20120258141Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system.10-11-2012
20120328664LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.12-27-2012
20120328663Composition of Beta-Glucan and Ashwagandha - Compositions including combinations of β-glucan and 12-27-2012
20120328661COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.12-27-2012
20120328662COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION - This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation.12-27-2012
20120269865NUTRITIONAL COMPOSITION FOR PROMOTING GUT MICROBIOTA BALANCE AND HEALTH - The present disclosure relates to nutritional compositions comprising a fructo-oligosaccharide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut microbiota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.10-25-2012
20120269863METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY - The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. The invention provides a method to promote T lymphocyte development using low dose Hedghog, and a method to inhibit T lymphocyte development using high dose Hedgehog. Certain aspects of the invention are directed to preparations of hedgehog polypeptides, agonists, antagonists, or other molecules which regulate patched or smoothened signalling, and their uses as immunomodulatory agents.10-25-2012
20120269862OPHTHALMIC COMPOSITION WITH A VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS - An ophthalmic composition is disclosed having a viscosity enhancement system comprised of two different viscosity enhancing agents. The aqueous composition contains a first viscosity enhancing agent that provides enhanced viscosity upon dispensing of the composition to the eye and a second viscosity agent that increases viscosity (e.g., gels or partially gels) after dispensing of the composition to the eye to provide extended viscosity enhancement of the composition.10-25-2012
20120269861TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS - In one aspect, the present invention provides a method of treating breast cancer that is negative for ER, PR, and HER2, comprising administering to a subject at least one iodonitrobenzamide. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one iodonitrobenzamide in combination with at least one anti-tumor agent.10-25-2012
20120269864Arginine Derivatives with NP-I Antagonistic Activity - The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.10-25-2012
20110236429Small Cationic Antimicrobial Peptides - The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.09-29-2011
20120321667T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS - The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.12-20-2012
20120321666T CELL THERAPY FOR B CELL LYMPHOMA - Disclosed are methods and compositions for improving anti-tumor response and survivability in patients with cancer, such as non-Hodgkin lymphoma. In certain aspects, methods are provided for infusing lymphoma patients with T cells that are propagated ex vivo. Also provided are methods and compositions for propagating canine T cells ex vivo for infusion into cancer patients.12-20-2012
20120087947USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS - The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.04-12-2012
20120282296METHODS FOR IMPROVING THE DESIGN, BIOAVAILABILITY, AND EFFICACY OF DIRECTED SEQUENCE POLYMER COMPOSITIONS VIA SERUM PROTEIN-BASED DETECTION OF DIRECTED SEQUENCE POLYMER COMPOSITIONS - There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of directed sequence polymers (DSPs), are complicated because DSPs are complex mixtures of peptides, as opposed to individual peptides with a defined amino acid sequence. This application provides improved methods of detecting and assessing DSP compositions, methods for the detection and quantitation of DSP compositions, means to determine and enrich a subset of peptides in a DSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering DSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above-mentioned methods for detection and quantitation.11-08-2012
20120288528MONO-AND DISACCHARIDE DERIVATIVES - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications.11-15-2012
20130017224Nucleic Acid Molecules Encoding Rantes, and Compositions Comprising and Methods of Using the Same - Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed.01-17-2013
20130017225NATURAL PLANT PRODUCTS FOR CONTROL OF CANCER METASTASIS - The invention provides compositions comprising soluble extracts or isolated polypeptides from the edible roots of the plant 01-17-2013
20130017223METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS - A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.01-17-2013
20130022642Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases - The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.01-24-2013
20130022641Anti-Tumor Agent and Immunostimulating Agent - To provide a pharmaceutical composition comprising a ceramide-related substance having little adverse side effects as an active ingredient by using a raw material that is highly safe to a human body and is inexpensive. A pharmaceutical composition comprising at least one sphingoglycolipid derivative that is produced from a beer waste and is represented by the formula below as an active ingredient: wherein R3 represents H or OH; R4 is as defined by (a) or (b) (a) when R3 is H, R4 represents (CH2)13CH3 or (CH2)6CH═CHCH2CH═CH(CH2)4CH3; and (b) when R3 is OH, R4 represents (CH2)yCH3 (where Y represents an integer of 13 to 21) or (CH2)Z1CH═CH(CH2)Z2CH3 (where Z1 and Z2 independently represent 0 or a natural number, provided that Z1+Z2=19).01-24-2013
20130171196Immunomodulatory Compounds for the Restoration of Vitamin D Sensitivity in Vitamin D Resistant Tumor Cells - Provided herein are methods of restoring vitamin D sensitivity in tumor cells that are vitamin D resistant. Also provided are methods of treating, preventing or managing cancer using an immunomodulatory compound in combination with a vitamin D agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.07-04-2013
20080226683Pharmaceutical Composition Including Clinoptilolite - The invention is for a method of potentiating clinoptilolite, the method including the steps of: providing fresh or spent clinoptilolite; exposing the clinoptilolite to a saline solution having a sodium ion content of about 10% to liberate impurities from the clinoptilolite; and drying the washed clinoptilolite fraction to render a potentiated clinoptilolite fraction. Preferably, the clinoptilolite is exposed to the saline solution for a period of about 48 hours. The washed clinoptilolite may be dried by filtered, heated air. This allows an optimal cation exchange capacity of the clinoptilolite to be reached. The clinoptilolite has uses as a medicament for a variety of aliments.09-18-2008
20080226682Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents - The present invention concerns methods and compositions for improved oral delivery of bioactive agents, such as vaccines. In preferred embodiments, the compositions comprise at least one lectin, saponin, polyunsaturated fatty acid and/or isoflavone. In further embodiments, the compositions may further comprise at least one protease inhibitor, buffer and/or surfactant. In more preferred embodiments, the lectins, saponins, fatty acids, isoflavones and/or protease inhibitors may be derived from extracts, homogenates, finely ground powders or derivatives of plant or animal material, such as beans, nuts, peas, fish meal or krill. The relative amounts of various naturally occurring materials contained in the compositions may be selected to optimize the concentrations of one or more lectins, saponins, polyunsaturated fatty acids and/or isoflavones. The compositions are of use for oral delivery of a wide variety of bioactive agents, particularly protein or peptide based agents.09-18-2008
20080226681Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production - The present invention relates to highly active glycoproteins with specific sialylation degrees, a pharmaceutical composition for use in diagnosis or therapy comprising the glycoproteins, a method for the determination of highly active glycoproteins and of the conditions for their production, a method for producing the highly active glycoproteins, and a method for differential sialylation of secretory glycoproteins. The invention also relates to the use of the recombinantly expressed highly active glycoproteins for biological purposes and for prophylactic and/or therapeutic treatment or diagnosis of diseases, particularly bone marrow transplantation, neutropenia, cytopenia, AML and myelodysplastic syndromes, cancer, HIV and/or diseases of hematopoietic systems.09-18-2008
20080226680Method and composition for delivery of medicants to animals - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method.09-18-2008
20130177596Endophytic Fungi from Pteromischum SP. Plant, Compounds and Methods of Use - The present disclosure relates to endophytic fungi from higher plants such as a 07-11-2013
20130177597Mango seed herbal medication - An herbal composition for treatment of kidney nephrotic syndrome formed of a mixture of the herbs mango seed powder, 07-11-2013
20120251582COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.10-04-2012
20120251581Novel Compound and Methods for its Production - There is provided inter alia a compound of formula (I):10-04-2012
20130095138Method and Apparatus for Producing a Stabilized Antimicrobial Non-toxic Electrolyzed Saline Solution Exhibiting Potential as a Therapeutic - An improved method and apparatus for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting electrolyzed saline solution exhibits a marked lack of toxicity upon intravenous, aspired, oral or topical application in mammals for therapeutic applications providing a broad platform, including topical disinfection, antimicrobial application, wound treatment, oxidative stress reduction and enhancement of immune function to better detect malfunctioning cells.04-18-2013
20130129785METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS - A lipid particle can include a cationic lipid. Synthesis of the cationic lipid can include a ylide-based reaction, such as a Wittig reaction or sulfur ylide reaction. In some cases, the synthesis can also include a Michael addition or a related addition reaction.05-23-2013
20080199499Method for Making Targeted Therapeutic Agents - Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair.08-21-2008
20130149341METHODS OF IMPROVING SKIN QUALITY - Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.06-13-2013
20120258144SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.10-11-2012
20100316676Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases - Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as 12-16-2010
20130156814METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS - The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.06-20-2013
200900812591-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect - The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane.03-26-2009
20130122050COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1 DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1 DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.05-16-2013
20130189311ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION - An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.07-25-2013
20130101627COMPOSITION WITH EXTRACTS FROM OLIVE LEAF, YARROW AND ROSEMARY FOR TREATING HUMAN DISEASES AND CONDITIONS - The present invention is a medical composition for treating a variety of human diseases and conditions. It comprises an effective amount of Olive Leaf extract, Yarrow extract and Rosemary extract as active components. Its inactive components include 04-25-2013
20130202648Immunoregulator Compounds - The invention relates to sphingosine derivative compounds, like D-erythro-sphingosine 08-08-2013
20130202646COMPOSITIONS AND METHODS FOR MODULATING AUTOPHAGY - In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including Crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as Trypanosomes and malaria.08-08-2013
20130202647Chloroplast Expression of Membrane Proteins - Disclosed herein are chloroplast transformation vectors constructed to enable expression and hyperaccumulation of membrane proteins in chloroplasts. Another embodiment relates to plants transformed with such vectors. Another embodiment relates to seeds and other plant tissues transformed with such vectors. Another embodiment relates to a method of increasing expression of membrane proteins in chloroplasts including transforming a plant cell with vectors described herein.08-08-2013
20130202649ACTIVATION OF INNATE IMMUNITY FOR NUCLEAR REPROGRAMMING OF SOMATIC CELLS - The nuclear reprogramming of somatic cells with non-integrating factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of toll-like receptors, e.g. TLR3. Somatic cells with activated innate immune responses can be reprogrammed to induced pluripotent cells or to transdifferentiated cells.08-08-2013
20130202650TOPICAL COMPOSITION COMPRISING A COMBINATION OF AT LEAST TWO PENETRATION ENHANCING AGENTS - The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least on the of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower alcohols, and iso-form alcohols; wherein at least one of the penetration enhancing agents is selected from the group consisting of aliphatic diols and triols; and wherein the components are present in a non-aqueous solvent system. A preferred topical composition comprises the active substance imiquimod and the penetration enhancing agents isoproply myristate and propylene glycol.08-08-2013
20130202651COMPOSITE VACCINE ADJUVANT - The invention provides a composite vaccine adjuvant, which is comprised of sodium ferulate and zinc hydroxide in a mass ratio of 10:1˜50:1. When the composite vaccine adjuvant and vaccine used in combination, the humoral immunity response is enhanced effectively, the enhanced effects is similar with aluminum adjuvant, superior to single sodium ferulate adjuvant and single zinc hydroxide adjuvant. It is not only atoxic, safety, but also reliable in the range of immune dose. The composite vaccine adjuvant with easily obtained and commercially available raw materials, is low cost, stable performance and simple preparation technology, which can be used as an adjuvant of hepatitis B vaccine, gene-engineered vaccine, virus vaccine and so on.08-08-2013
201302026533-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINOPROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY - Compounds of Formulas 1 and 208-08-2013
20130202652METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS - A targeting lipid can have the formula (I) in which T4 is a targeting moiety. The targeting moiety can be chosen to favor the lipid being localized with a desired organ, tissue, cell, cell type or subtype, or organelle. The targeting moiety can include, for example, transferrin, anisamide, an RGD peptide, prostate specific membrane antigen (PSMA), fucose, an antibody, or an aptamer.08-08-2013
20120093874METHOD FOR SCREENING FOR DIET PROVIDING PRODUCTION OF MILK HAVING IMMUNOREGULATORY ACTION - A method for screening for a foodstuff providing production of milk having an immunoregulatory action, a novel foodstuff having an immunoregulatory action, and a method for producing it are provided. A diet or substance that increases or decreases an amount of microRNA present in milk of a mammal is identified by using correlation of microRNA profiles in the milk and a diet ingested by the mammal or a substance contained in the diet as an index to screen for a diet or a substance providing production of breast milk having an immunoregulatory action.04-19-2012
20120093873Molecular Interactions in Hematopoietic Cells - The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.04-19-2012
20130209516IMMUNOMODULATORY COMPOSITIONS - Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula (I), wherein R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof, are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, haemorestoration, alleviation of immuno-suppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells.08-15-2013
20130209515ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS - The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression or activity of individual virulence factors. In addition, the compositions have immunomodulatory activity, and therefore can be used to prime host defenses to prevent or limit bacterial, fungal, and viral viability. In the compositions and methods of the inventions, specific steps of the bacterial-, fungal-, or viral-host interaction are targeted to prevent pathogenesis (e.g., infection). Such an approach should prevent pathogenic organisms from acquiring resistance to the protective anti-infective compounds.08-15-2013

Patent applications in class NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR

Patent applications in all subclasses NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR